In CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer, PRMT5 inhibition represents a viable therapeutic strategy, leading to the dissociation of FUS from RNA polymerase II and subsequently suppressing the DNA synthesis (28). Here, RB1 is linked to breast carcinoma.